dostarlimab,pembrolizumab
gsk,merck
['nsclc', 'sclc', 'dostarlimab', 'perla trial', 'pembro', 'aster,70', 'dostar ']
#esmoimmuno22 perla trial with 's great presentation: first study comparing two anti-pd1 agents in nsclc. dostarlimab met primary endpoint. comparisons of drugs in the same group are very valuable in order to decrease drug prices. 
MD, Associate Professor, Medical Oncologist and Internal Medicine specialist. #breastcancer #colorectalcancer #lungcancer #precisionmedicine #HealthForAll